A Democrat and a Republican have introduced legislation in Congress that would overturn a July CMS decision to restrict reimbursements for erythropoiesis-stimulating drugs that treat anemia in cancer patients. The legislation says the CMS policy puts patients at risk by restricting access to the drugs, including Amgen's Epogen and Aranesp and Johnson & Johnson's Procrit.

Full Story:
Hill, The

Related Summaries